INTRODUCTION {#s1}
============

It was reported that about 14% gastric cancer patients developed hepatic metastasis, and more than 30% gastric cancer patients developed metachronous liver metastasis after surgical resection of the primary gastric cancer \[[@R1]\]. Although previous studies \[[@R2]--[@R32]\] reported that hepatectomy may provide an opportunity of long-term survival in these patients (Table [1](#T1){ref-type="table"}), most of these studies were conducted on the single-institution basis including no more than 50 cases, and therefore the beneficial effect of hepatectomy are not well-defined. The objective of this study was to analyze the outcome of surgical resection of hepatic metastasis from gastric cancer (HMGC) and determine prognostic factors associated with survival in a relatively large multi-institution cohort of patients.

###### Literature overview of outcomes following hepatectomy for metastatic gastric cancer

  --------------------------------------------------------------------------------------------------------------------
  Reference                     Year   Country   Study\       No. of\    Mortality (%)   3-year\   5-year\   MST\
                                                 interval     patients                   OS (%)    OS (%)    (months
  ----------------------------- ------ --------- ------------ ---------- --------------- --------- --------- ---------
  Ambiru et al. \[[@R2]\]       2001   Japan     1975--1999   48         0               --        18        12

  Imamura et al. \[[@R3]\]      2001   Japan     1990--1997   17         0               22        0         --

  Okano et al. \[[@R4]\]        2002   Japan     1986--1999   19         0               34        34        --

  Zacherl et al. \[[@R5]\]      2002   Austria   1980--1999   15         6.7             14.3      0         8.8

  Sakamoto et al. \[[@R6]\]     2003   Japan     1985--2001   22         5               38        38        21

  Shirabe et al. \[[@R7]\]      2003   Japan     1979--2001   36         0               26        26        --

  Adam et al. \[[@R8]\]         2006   France    1983--2004   64         --              --        27        15

  Sakamoto et al. \[[@R9]\]     2007   Japan     1990--2005   37         0               --        11        31

  Cheon et al. \[[@R10]\]       2008   Korea     1995--2005   41         3               31.7      20.8      17

  Morise et al. \[[@R11]\]      2008   Japan     1989--2004   18         0               27        27        13

  Thelen et al. \[[@R12]\]      2008   Germany   1988--2002   24         4.2             22        15        10

  Ueda et al. \[[@R13]\]        2009   Japan     1991--2005   15         0               60        60        --

  Makino et al. \[[@R14]\]      2010   Japan     1992--2007   16         0               46.4      37.1      38.3

  Tsujimoto et al. \[[@R15]\]   2010   Japan     1980--2007   17         0               37.5      31.5      34

  Dittmar et al. \[[@R16]\]     2012   Germany   1995--2009   15         0               54        27        48

  Garancini et al. \[[@R17]\]   2012   Italy     1998--2007   21         0               31        19        11

  Miki et al. \[[@R18]\]        2012   Japan     1995--2009   25         --              42.8      36.7      33.4

  Schildberg et al.\[[@R19]\]   2012   Germany   1972--2008   31         6               25        13        14

  Takemur et al. \[[@R20]\]     2012   Japan     1993--2011   64         0               50        37        34

  Wang et al. \[[@R21]\]        2012   China     2003--2008   30         0               16.7      16.7      11

  Baek et al. \[[@R22]\]        2013   Korea     2003-2010    12         0               39        39        31

  Chen et al. \[[@R23]\]        2013   China     2007--2012   20         0               20        --        22.3

  Qiu et al. \[[@R24]\]         2013   China     1998--2009   25         0               70.4      29.4      38

  Komeda et al. \[[@R25]\]      2014   Japan     2000--2012   24         0               40.1      40.1      22.3

  Wang et al. \[[@R26]\]        2014   China     1996--2008   35         0               17.9      10.3      14

  Kinoshita et al. \[[@R27]\]   2015   Japan     1990--2010   256        1.6             77.3      41.9      31.1

  Shinohara et al. \[[@R28]\]   2015   Japan     1995--2010   19         0               31.7      31.7      27

  Tiberio et al. \[[@R29]\]     2015   Italy     1997--2011   53         --              14        9.3       13

  Oki et al. \[[@R30]\]         2016   Japan     2000--2010   94         --              51.4      42.3      40.8

  Tiberio et al. \[[@R31]\]     2016   Italy     1990--2013   105        0.9             20.3      13.1      14.6

  Markar et al. \[[@R32]\]      2017   UK        1997--2012   78         10.3            42        31        --
  --------------------------------------------------------------------------------------------------------------------

Abbreviations: MST = median survival time; OS = overall survival.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

The study group included 72 (75%) men and 24 (25%) woman with a median age of 63 (range 32--78) years. Of these, 59 (61.5%) patients presented with synchronous liver metastases and 37 (38.5%) presented with metachronous liver metastases. In the latter group, the median interval between gastrectomy and hepatectomy for hepatic metastasis was 8.7 months (range, 4--32 months). Forty-two (43.7%) patients presented with solitary lesions, and 54 (56.3%) had multiple lesions. Ninety-one (94.8%) patients achieved curative resection. Fifty-eight (60.4%) patients received adjuvant therapy after hepetectomy.

Results of surgical resection {#s2_2}
-----------------------------

There was no intra- or postoperative mortality. A total of 63 complications occurred in 46 patients (47.9%), of whom 11 (11.4%) patients had major morbidities (Clavien-Dindo ≥ 3a).

During the median follow-up period of 33 months, 77 (80.2%) patients experienced recurrences. The most frequently site of recurrence was the liver (*n* = 45, 58.4%), followed by the lymph node (*n* = 11, 14.3%), peritoneum (*n* = 8, 10.3%), and lung (*n* = 8, 10.3%). Details of the recurrences were unknown in 5 cases (6.5%). Only 3 (6.7%) of the 45 patients with liver recurrences underwent re-hepatectomy.

The 1-, 3- and 5-year overall survival (OS) rate of the entire cohort of patients after surgery was 87.5%, 47.6% and 21.7%, respectively, with a median survival time of 34.0 months (Figure [1](#F1){ref-type="fig"}). Several factors were found to be associated with poor prognosis in univariate analysis (Table [2](#T2){ref-type="table"}). Multiple liver metastases (hazard ratio \[HR\] = 1.998; 95% confidence interval \[CI\] = 1.248--3.198; *P* = 0.004) and ≥ T3 stage of the primary gastric cancer (HR = 2.065; 95% CI = 1.201--3.549; *P* = 0.009) were independent prognostic determinants, as shown by multivariate analysis.

![Cumulative overall survival for patients who underwent resection for hepatic metastasis from gastric cancer](oncotarget-08-71147-g001){#F1}

###### Univariate analysis of prognostic factors for overall survival

  Variables                             Number   MST (months)   *P*-value
  ------------------------------------- -------- -------------- -----------
  Gender                                                        
   Male                                 72       40             0.714
   Female                               24       28             
  Age                                                           
   ≥ 65                                 51       36             0.739
   \< 65                                45       34             
  T stage of gastric cancer                                     
   \< T3                                47       46             0.007
   ≥ T3                                 59       24             
  Lymph node status of gastric cancer                           
   N0-N1                                28       45             0.015
   N2-N3                                68       30             
  Histologic grade of gastric cancer                            
   Well-moderate                        62       42             0.032
   Poorly                               34       29             
  Histologic type of gastric cancer                             
   Intestinal                           61       44             0.058
   Diffuse                              12       17             
  Type of gastrectomy                                           
   Total gastrectomy                    33       22             0.373
   Subtotal gastrectomy                 63       40             
  Timing of hepatic metastasis                                  
   Synchronous                          59       43             0.167
   Metachronous                         37       33             
  Type of hepatectomy                                           
   Major (≥ 3 segments)                 35       34             0.456
   Minor (\< 3 segments)                61       36             
  Curative resection                                            
   Yes                                  91       39             0.031
   No                                   5        27             
  Maximum hepatic metastasis size                               
   \< 5 cm                              71       44             0.069
   ≥ 5 cm                               25       28             
  Number of metastases                                          
   Solitary                             42       42             0.021
   Multiple                             54       29             
  Distribution of liver metastases                              
   Unilobar                             57       41             0.394
   Bilobar                              29       32             
  Morbidity                                                     
   Yes                                  46       40             0.237
   No                                   50       31             
  Adjuvant chemotherapy                                         
   Yes                                  58       42             0.172
   No                                   38       35             

Abbreviations: MST = median survival time.

DISCUSSION {#s3}
==========

Although solid clinical evidence exists to support surgical resection as the optimal option for the treatment of colorectal liver metastasis (CLM), data evaluating the postoperative outcome of HMGC are limited and controversial (Table [1](#T1){ref-type="table"}). This may be explained by the fact that most patients with HMGC presented with multiple lobar metastases, gross peritoneal dissemination, extensive lymph node metastases, distant metastasis, or direct invasion to other organs at time of diagnosis, and therefore were considered unamenable to surgery \[[@R5]\]. It was reported that patients with potentially resectable HMGC treated with systemic chemotherapy had a median survival of 5.5 months, and the number of 3-year survivors was zero \[[@R23]\]. A systematic review of 870 patients from 23 studies performed by Petrelli and colleagues in 2015 demonstrated that resection of HMGC was associated with a 22-month median survival and a 23.8% 5-year OS rate \[[@R33]\]. A similar systematic review was published by Markar et al in 2016, which included 991 patients and come to similar conclusions, with a median 5-year OS of 27% \[[@R34]\]. In accordance with these two reports, the present study also confirmed the benefit of surgical resection for HMGC in achieving long-term survival in a relatively large cohort of patients drawn from multi-centers in China. The 5-year OS rate after surgery was 21.7% with a median survival time of 34.0 months.

Safety is an important concern in such an aggressive management strategy. Hepatic resection of metachronous liver disease is technically demanding because of intra-abdominal adhesions caused by previous surgery. Synchronous resection of the HMGC and primary tumor may be associated with increased post-operative complications. However, in the present study and previous reports, resection could be safely performed with acceptable operative mortality and morbidity \[[@R19]--[@R28]\]. It should be noted that this favourable outcome may be attributed to careful selection of patients with limited disease, as reflected by major hepatectomy is not performed frequently \[[@R27]\]. In addition, patients with HMGC usually had no underlying cirrhosis, a factor associated with a high risk of postoperative liver failure because of the limited regenerative capacity of the liver remnant.

Multivariate analysis in our series disclosed that multiple liver metastases and ≥ T3 stage of the primary gastric cancer were independent prognostic determinants. These data may have important implications in helping select patients for surgical resection. There is evidence that postoperative complications, especially major complications, have a negative impact on long-term survival after oncological surgery \[[@R35]\]. Immunosuppression secondary to septic complications may increase the growth of occult micrometastasis, and some complications may make patients unfit for adjuvant therapy or delay the time interval. However, we did not find that OS was significantly reduced in patients with complications in our study. The fact that there were only 11.4% of patients with major complications in current study, it is possible that failure to detect a clinically significant difference represents a type-II error.

Percutaneous radiofrequency ablation (RFA) is generally accepted as a safe, effective and minimally invasive treatment for patients with CLM \[[@R36]\]. However, few studies have focused on RFA for HMGC. RFA may contribute to local control of single liver-only metastatic lesions \[[@R37]\]. No reliable data on the comparative therapeutic efficacy of RFA and hepatic resection for resectable HMGC are available at present, and therefore RFA should not be recommended as an alternative to surgical resection at this disease stage.

Recurrence following surgical resection of HMGC is common and mostly occurs in the remaining liver tissue. Repeat hepatectomy seems beneficial to patients with solitary intrahepatic recurrence \[[@R25], [@R27]\]. Unfortunately, very few patients are potential candidates for hepatic resection because of extensive metastases \[[@R27]\].

The efficacy of adjuvant chemotherapy after liver resection of HMGC remains unclear. Qiu et al. \[[@R24]\] reported that patients who received adjuvant chemotherapy had significantly better survival. However, our and other studies \[[@R9], [@R25], [@R27]\] were unable to confirm their conclusion. These different findings may be explained by differences in the regimens used, the timing and duration of cytotoxic agent administration, and patient selection between these studies. Unlike CLM, it seems impossible to test the clinical significance of adjuvant chemotherapy for HMGC in a prospective manner because of the rarity of candidates \[[@R27]\].

The study has some limitations, including the retrospective nature and possible bias in patient selection. More data are needed to further verify the conclusion of the present study.

In conclusion, this large-cohort study has demonstrated that surgical resection for HMGC is feasible and beneficial to long-term survival in selected patients.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

Included in this study were 96 patients who underwent surgical resection for HMGC between January 2001 and January 2012 in six medical institutions in China. The study was approved by the ethics committee of each contributing institution. Written informed consent forms were not required from the patients due to the retrospective approach of the study. In general, surgical resection of HMGC followed the following criteria: (1) curative resection (microscopic tumor removal based on the histopathologic evaluation) of the primary tumor and liver metastasis thought to be technically accessible; and (2) no sign of concomitant extrahepatic metastasis on preoperative imaging. Data were collected retrospectively by reviewing the medical records, including patient age and sex at hepatic resection; pathological characteristics of the primary gastric cancer and hepatic metastasis; and short- and long-term outcomes after surgery. Postoperative mortality was defined as any death occurring within 30 days of surgery or within the same hospital stay. Postoperative complications were defined as occurrence of any medical or surgical complication during the hospital stay and graded according to the Clavien-Dindo classification \[[@R38]\]. The primary tumor stage and regional lymph node status were classified according to the 7th edition of the International Union Against Cancer of gastric cancer \[[@R39]\]. The types of hepatectomy were classified in accordance with the Brisbane 2000 nomenclature \[[@R40]\].

Statistical analysis {#s4_2}
--------------------

Overall survival was determined by Kaplan-Meier analysis. Factors related to survival selected by univariate analysis with *P* \< 0.05 were entered into a multivariate analysis using Cox proportional hazard regression model to determine the independent risk factors for survival. All statistical analyses were performed using SPSS for Windows (version 11.0; SPSS Institute, Chicago, IL, USA). *P* \< 0.05 was considered statistically significant.
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